Member Info for AdamKahn

I asked chat gpt to highlight the key indicators for someone to make a decision to purchase a stock, it gave me these 5.

1: Moving Averages (MA):

2: MACD

3: Relative Strength Index

4: Stochastic

5: Commodity Channel Index

I asked it then to measure HEMO against these and the results are as follows

1. Moving Averages (MA):

All key MAs from 5-day to 200-day are trending upward—which signals strong bullish momentum. The shorter-term MAs (MA5 and MA10) are significantly below the current price, enhancing this bullish stance. 

2. MACD (50.486):

Well into positive territory, which typically indicates strong upward momentum. 

3. Relative Strength Index – RSI (70.018):

Hovering near the 70 level, which often suggests overbought conditions. It may warrant caution—especially if you’re considering entry points or anticipating pullbacks. 

4. Stochastic (66.955) & Williams %R (–27.622):

These momentum oscillators are in neutral zones—not strongly overbought or oversold—indicating room for the trend to continue. 

5. Commodity Channel Index – CCI (93.377):

Slightly elevated, yet still below levels (e.g., 100+) typically associated with overbought extremes.

Indicator

Value & Signal

Interpretation

MA5–MA200

All trending up (various numeric levels)

Strong bullish trend across multiple timeframes

MACD

50.486 (positive)

Solid upward momentum

RSI (14)

70.018 (near overbought threshold)

Vigilance advised: could signal an approaching correction

Stochastic

~66.96 (neutral)

Momentum remains positive but not extreme

Williams %R

–27.62 (neutral)

No immediate overbought/oversold signal

CCI

93.38 (elevated but safe)

Healthy momentum, not yet at extreme levels

(Not financial advice and please do your own research)

Was bored on a Sunday afternoon so thought let’s try some AI personas.

Good luck all and all the best

Shorted getting burned! Ha ha ha love it!

Any who try’s to destroy a company who is on the cusp of bringing life changing benefits to people can frankly got to h e l l

Chat Gpt summarised the content of the podcast. if you want the lottery numbers go and ask mystic Meg

Projected Time Frame for P140 Development & Commercial Milestones

Milestone

Estimated Time Frame

Details

🔬 Phase 3 (SLE - Lupuzor™)

Ongoing (2025–2026)

Trial active; aim to incorporate Type M diagnostic to refine patient group.

🧪 Phase 2/3 (CIDP)

Start by late 2025 / early 2026

Pre-IND discussions with FDA ongoing; Orphan Drug application in progress.

🧬 Companion Diagnostic Rollout

Initial validation by Q4 2025

Diagnostic tool to identify Type M patients for trials and commercial use.

🔐 Patent Lifecycle Extension

Effective immediately (2025–2045)

New patent grants up to 20 years’ exclusivity across therapy + diagnostic.

🤝 Partnering / Licensing Discussions

Expected from Q4 2025 onwards

Actively engaging with potential pharma partners; new patent increases appeal.

💊 Commercial Readiness (SLE/CIDP)

2027–2028 (if trials succeed)

Subject to trial results and regulatory approvals. Early access possible in CIDP via Orphan Drug pathway.

Near-Term Focus (Q4 2025 – 2026)

• Validate and deploy Type M diagnostic.

• Advance clinical trials with enriched patient selection.

• Secure regulatory designations (e.g., Orphan Drug).

• Start active BD/partnership discussions.

🚀 Medium-Term Outlook (2026–2028)

• Potential trial readouts and regulatory submissions.

• Launch in first indication (SLE or CIDP), depending on trial progress.

• Expand into other autoimmune diseases using P140 + diagnostic platform.

Next Steps for P140 & ImmuPharma

1. Advance Clinical Trials

• SLE (Lupus)

• Continue the international Phase 3 trial of P140 (Lupuzor™).

• Leverage the Type M diagnostic to enrich the patient population with super-responders — improving trial success probability.

• CIDP (Chronic Inflammatory Demyelinating Polyneuropathy)

• Prepare for a Phase 2/3 adaptive trial.

• Ongoing regulatory dialogue with the FDA.

• Applying for Orphan Drug Designation to secure market exclusivity and expedited pathways.

⸻

2. Expand Use of Type M Diagnostic

• Roll out the new companion diagnostic to:

• Identify Type M patients across other autoimmune diseases.

• Support additional clinical indications beyond SLE and CIDP.

⸻

3. Strengthen IP & Patent Strategy

• Broaden the patent to:

• Cover more indications and geographies.

• Extend market exclusivity through 2045+.

⸻

4. Seek Strategic Partnerships

• Engage with pharma partners for:

• Co-development or licensing of P140.

• Joint commercialization of both drug + diagnostic as a precision therapy platform.

⸻

5. Communicate Value to Investors

• Capitalize on strong investor momentum following the patent news.

• Reinforce P140’s platform potential to position ImmuPharma as a leader in precision immunology.

P140 doesn’t just treat — it redefines how autoimmune diseases could be managed, by combining safety, precision, and long-term disease control.

P140: A First-in-Class “Immunormalizer” with Transformational Potential

🧩 What is P140?

P140 is ImmuPharma’s lead asset — a first-in-class peptide-based drug with a completely novel mechanism of action. Unlike traditional immunosuppressants, which blunt the entire immune system, P140 selectively restores immune tolerance — rebalancing the immune system without compromising its ability to defend the body.

💡 This is why it’s being called the first “Immunormalizer” — a new category in autoimmune treatment.

⸻

💡 Why P140 is a Potential Game-Changer

✅ 1. Breakthrough Patent & New Disease Subtype (Type M)

• ImmuPharma has secured a new patent for P140 + a companion diagnostic that identifies patients with Type M immune disorder — a subgroup of autoimmune patients who are “super-responders” to P140.

• This patent protects both the drug and the diagnostic, providing a targeted, precision-medicine strategy.

🔹 Type M patients are believed to exist across 50+ autoimmune diseases, giving P140 broad potential.

⸻

✅ 2. Massive Market Opportunity

• $100+ billion global market for autoimmune disease therapies.

• $10+ billion for companion diagnostics.

• P140 could capture significant share by:

• Offering a safer, non-immunosuppressive alternative,

• Enabling personalized treatment via the diagnostic,

• Reducing trial risk by selecting likely responders.

🎯 Most autoimmune drugs treat symptoms — P140 targets the cause in a way no other drug does.

⸻

✅ 3. Strong Clinical and Preclinical Signals

• Phase 2 and 3 data in Lupus (SLE) show promising efficacy and safety.

• P140 is also being advanced for:

• CIDP (Chronic Inflammatory Demyelinating Polyneuropathy)

• Other autoimmune and inflammatory conditions: asthma, gout, IBD, periodontitis.

📈 The pipeline potential goes far beyond one disease.

⸻

✅ 4. Validated Safety Profile

• Unlike biologics that increase infection risk, P140 does not suppress the immune system.

• This could be a major differentiator in terms of:

• Regulatory approval,

• Adoption by doctors and patients,

• Fewer long-term side effects.

⸻

✅ 5. Commercial and Scientific Validation

• Following the patent announcement, ImmuPharma’s share price more than doubled.

• Leadership strengthened: Dr Sébastien Goudreau promoted to CSO after leading the scientific work behind the new patent.

• Multiple partnering opportunities are emerging thanks to the drug + diagnostic model.

Key Pillar

What It Means

Novel MOA & Safety

Offers a safer, restorative alternative to immunosuppression in autoimmune care.

Precision Stratification

Targets super‑responders (Type M), improving trial success and clinical outcomes.

Extensive Pipeline

SLE and CIDP advanced in clinic, with additional indications on preclinical track.

Strong IP Positioning

Long-term exclusivity and broader patent coverage enhance commercial value.

Market Validation

Investor response and leadership alignment reinforce strategic momentum.

Summary

This episode spotlights ImmuPharma’s strategic advancement through its patented Immunormalizer, P140—an integrated diagnostic-treatment innovation. Targeting “super-responder” patients with Type M immune disorder, the asset taps into multi-billion-dollar markets and reinforces the company’s leadership in precision-driven autoimmune therapy.

In this episode, the hosts dive into ImmuPharma’s breakthrough: a newly filed “groundbreaking” patent for their lead asset, P140, branded as the world’s first “Immunormalizer”   . It introduces a pioneering precision-based therapeutic and diagnostic approach targeting a newly identified subgroup: those with the Type M immune disorder, who are termed “P140 super‑responders.” This dual modality offers both treatment and patient stratification across up to 50 autoimmune diseases   .

The episode unpacks the immense market potential: roughly $100 billion in treatment and an additional $10 billion in diagnostics  . Emphasis is placed on how the combined therapeutic and diagnostic offering enhances partnering attractiveness and positions ImmuPharma for market transformation in autoimmune disease management.

Underlying Science & Strategic Context

1. Mechanism of Action (MOA): A True Immunormalizer

Unlike traditional immunosuppressants, P140 restores immune balance (homeostasis) without weakening immune defense. It uniquely enables tolerogenic antigen-presenting cells to function properly, tackling the root tolerance dysfunction seen in autoimmune diseases   .

Preclinical studies support P140’s non-immunosuppressive nature, reinforcing its safety and effectiveness, particularly for conditions such as systemic lupus erythematosus (SLE)  .

2. Broad Clinical Pipeline

• SLE (Lupuzor™): P140 has entered a pivotal Phase 3 dose-range international trial, following promising pharmacokinetic results and refined protocols .

• CIDP: Planning for a Phase 2/3 adaptive trial is underway, with FDA engagement already secured. Orphan Drug designation is anticipated, potentially accelerating path to market and offering extended exclusivity .

• Other Indications: Early-stage data suggest P140’s applicability in conditions like asthma, periodontitis, gout, and IBD, further solidifying its platform potential .

3. Strategic Intellectual Property Expansion

ImmuPharma is actively bolstering its IP portfolio:

• A new strategy extends patent life and coverage across multiple indications .

• The recent patent filing delivers potential 20-year exclusivity on the “Immunormalizer” approach and companion diagnostic, especially for the Type M subgroup   .

4. Commercial Momentum & Market Reception

The patent announcement sparked a sharp leap in ImmuPharma’s share price, more than doubling to 4.76 pence, reflecting strong investor confidence in the strategic value of the

Great interview, much more in depth with a focus on deals in the making, how the mechanism works, who it works on. Have a listen and tell you not excited with everything Tim is saying.

Look like some heavy resistance at 800 and 860….. blue sky after that??

Thanks for for this what about the bid side please

all those ramping the crap out of this should be ashamed, it’s going to €20.00 level 2 says this and level 2 says that what a load of bull****!

stick to the facts and the science and everything else is noise, fair play to those who have made money and to the naysayers i say get a life! the science works, the company will come good as will the share price, patient is key and personally i have added twice today ( sold my imm) but please don’t tell them over there, imm will too come good, it’s not that i don’t like imm i just like hemo more.

Can you explain what this means, some off us are new to L2. Ask depth etc

Thanks

IMM missed a trick and should have mentioned Jackson’s lab in the RNS!

Who are Jackson’s lab that have confirmed IMM’s findings?

Market outlook is not a great read is it?

I guess there lots newbies around who could and possibly would have got nervous when someone ones calls out that a share is being shorted, I know lots of people personally (me included) who don’t touch shares that are being shorted, I have done my research on hemo and trust the Science, but not everyone has. I don’t think Matt is being malicious just my thoughts. All the best

A lot of people have made some serious money here since last weeks raise, im guessing people just selling to enjoy profits, fundamentally nothing has changed, just a great company with some great LTH to benefit us with their research

Tim says deal(s) in the pipeline and next source of revenue from licensing deals. He says by end of year, I think next 6 months.

Good move and well done. I’m sitting on average of 2.6p with half a million shares, nearly sold at 5.5p yday, but got nervous lol. I can lie and say I did sold all my holding at 5.5 and bought back at 4p but I’d be lying to myself! I could have a made a ton of money on this share buy I’m not one to time my entries lol!